Halozyme Therapeutics: Q4 Earnings Insights - Halozyme Therapeutics (NASDAQ:HALO)

Halozyme Therapeutics HALO reported its Q4 earnings results on Tuesday, February 20, 2024 at 04:01 PM.

Here's what investors need to know about the announcement.

Halozyme Therapeutics missed estimated earnings by 1.2%, reporting an EPS of $0.82 versus an estimate of $0.83.

Revenue was up $48.54 million from the same period last year.

Last quarter the company beat on EPS by $0.02 which was followed by a 10.04% increase in the share price the next day.

Here's a look at Halozyme Therapeutics's past performance:

Quarter	Q3 2023	Q2 2023	Q1 2023	Q4 2022
EPS Estimate	0.73	0.63	0.48	0.47
EPS Actual	0.75	0.74	0.47	0.48
Revenue Estimate	222.63M	199.32M	175.51M	192.05M
Revenue Actual	216.03M	221.04M	162.14M	181.50M

To track all earnings releases for Halozyme Therapeutics visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.